Skip to main content
PEPG
NASDAQ Life Sciences

PepGen Q3 Cash Falls to $104.8M; Runway Extended Into 2028 on FREEDOM2 Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.4
Mkt Cap
$165.53M
52W Low
$1.31
52W High
$7.8
52W Position info
83% above low
Off High info
69% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

PEPG sits 83% above its 52-week low of $1.31.

Summary

PepGen ended Q3 with $104.8 million in cash and securities and now expects that to fund operations into 2028, while the lead DM1 program stays on U.S. partial clinical hold ahead of 12.5 mg/kg data in the first half of 2027.


Key Events · Earnings and Guidance · PEPG

  • Q3 Cash Position and Runway

    Cash, cash equivalents and marketable securities totaled $104.8 million at September 30, 2026, down from $117.2 million at the prior 10-Q; management says this funds planned operations into 2028.

  • Quarterly and Year-to-Date Losses

    Net loss was $19.4 million for Q3 2026 and $55.0 million for the nine months, versus $71.3 million in the prior-year nine-month period.

  • FREEDOM2 10 mg/kg Data

    The 10 mg/kg cohort showed 46.5% mean splicing correction at week 13 versus 6.8% in pooled placebo, with no serious adverse events reported.

  • U.S. Partial Clinical Hold Persists

    FREEDOM2 remains on partial clinical hold in the U.S.; the company is running additional nonclinical mouse studies to respond to FDA feedback.


Analysis · PEPG · Life Sciences

Liquidity fell by roughly $12.4 million during the quarter, leaving PepGen with $104.8 million in cash and securities at September 30 against a $19.4 million quarterly net loss. Management now expects that cash to fund planned operations into 2028, later than the prior 'late 2027' runway, which buys time before another raise. The clinical story is the swing factor: the 10 mg/kg FREEDOM2 cohort showed 46.5% mean splicing correction versus 6.8% for placebo at week 13, but the FREEDOM2 study remains on partial clinical hold in the U.S., and the 12.5 mg/kg readout is now guided to the first half of 2027 with an end-of-Phase 2 FDA meeting targeted for the second half of 2027. Investors are effectively underwriting a binary 2027 catalyst while the company funds itself into 2028.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PEPG was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.5M. The 52-week trading range was $1.31 to $7.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PEPG - Latest Insights

PEPG
Nov 10, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $2.40
Real-time Price: $2.40 info
Change: $0 (0%) info
Market Cap: $165.53M info
PEPG
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $2.40 info
Change: -$0.400 (-14%) info
Market Cap: $165.53M info
PEPG
Aug 06, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.10
Real-time Price: $2.40 info
Change: +$0.300 (+14%) info
Market Cap: $165.53M info
PEPG
Aug 06, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $2.40 info
Change: +$0.250 (+12%) info
Market Cap: $165.53M info
PEPG
Aug 06, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $1.96
Real-time Price: $2.40 info
Change: +$0.440 (+22%) info
Market Cap: $165.53M info